Measuring patient-reported physical functioning and fatigue in myelodysplastic syndromes using a modular approach based on EORTC QLQ-C30

por Regnault, Antoine, Pompilus, Farrah, Ciesluk, Anna, Mazerolle, Flora, Bejar, Rafael, Fram, Robert J., Faller, Douglas V., Marquis, Patrick, Bell, Jill A.
Publicado 2021

Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States

por Bell, Jill A., Galaznik, Aaron, Blazer, Marlo, Shih, Huai-Che, Farrelly, Eileen, Ogbonnaya, Augustina, Eaddy, Michael, Fram, Robert J., Faller, Douglas V.
Publicado 2018

A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia,...

por Bell, Jill A., Galaznik, Aaron, Pompilus, Farrah, Strzok, Sara, Bejar, Rafael, Scipione, Fatima, Fram, Robert J., Faller, Douglas V., Cano, Stefan, Marquis, Patrick
Publicado 2019

Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes

por Zeidner, Joshua F., Mazerolle, Flora, Norton, Jonathan, Regnault, Antoine, Kristo, Fjoralba, Romero, Heather, Fram, Robert J., Faller, Douglas V., Dalal, Mehul, Ades, Lionel, Sekeres, Mikkael A.
Publicado 2022

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML

por Sekeres, Mikkael A., Watts, Justin, Radinoff, Atanas, Sangerman, Montserrat Arnan, Cerrano, Marco, Lopez, Patricia Font, Zeidner, Joshua F., Campelo, Maria Diez, Graux, Carlos, Liesveld, Jane, Selleslag, Dominik, Tzvetkov, Nikolay, Fram, Robert J., Zhao, Dan, Bell, Jill, Friedlander, Sharon, Faller, Douglas V., Adès, Lionel
Publicado 2021

Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML

por Sekeres, Mikkael A., Watts, Justin, Radinoff, Atanas, Sangerman, Montserrat Arnan, Cerrano, Marco, Lopez, Patricia Font, Zeidner, Joshua F., Campelo, Maria Diez, Graux, Carlos, Liesveld, Jane, Selleslag, Dominik, Tzvetkov, Nikolay, Fram, Robert J., Zhao, Dan, Bell, Jill, Friedlander, Sharon, Faller, Douglas V., Adès, Lionel
Publicado 2021

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML

por Adès, Lionel, Girshova, Larisa, Doronin, Vadim A., Díez-Campelo, María, Valcárcel, David, Kambhampati, Suman, Viniou, Nora-Athina, Woszczyk, Dariusz, De Paz Arias, Raquel, Symeonidis, Argiris, Anagnostopoulos, Achilles, Munhoz, Eduardo Ciliao, Platzbecker, Uwe, Santini, Valeria, Fram, Robert J., Yuan, Ying, Friedlander, Sharon, Faller, Douglas V., Sekeres, Mikkael A.
Publicado 2022